Compare iShares MSCI Singapore ETF (EWS) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Smith & Nephew plc — how do they compare? iShares MSCI Singapore ETF trades at $31.6 (market cap $1.49B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 7.4× iShares MSCI Singapore ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while iShares MSCI Singapore ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Singapore ETF for 45 Days and Smith & Nephew plc for 121 Days on average.
| EWS | SNN | |
|---|---|---|
Market Cap | $1.49B | $11.10B |
Volume | 2,142,305 | 1,051,703 |
Sector | Broad Market / Factor | Health |
52-Week High | $34.57 | $37.17 |
52-Week Low | $26.71 | $26.42 |
Typical Hold Time | 45 Days | 121 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS (iShares MSCI Singapore ETF) trades at $31.60, down 2.71% with bearish technical signals from moving averages and oscillators. The ETF recently hit 52-week highs amid Singapore's strong economic growth and AI momentum, attracting institutional interest including Amundi's 4.8% position increase. Key support sits at $31 with resistance at $32.
Outlook remains mixed with technical weakness offset by positive fundamental drivers. Investment opportunity lies in Singapore's economic resilience and AI-driven growth, though stretched valuations and bearish momentum present near-term risks. The ETF offers exposure to Asia's outperformance versus S&P 500 but faces volatility from regional economic sensitivity.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
